InvestorsHub Logo
Followers 36
Posts 1736
Boards Moderated 0
Alias Born 05/13/2011

Re: None

Wednesday, 05/27/2020 11:47:08 AM

Wednesday, May 27, 2020 11:47:08 AM

Post# of 17503
Are we ready for ARIA 2.0? kidding. but this time reminds me of how exciting it was post brigatinib phase 3 readout...the possiblities seemed endless.. BTW on 5/22/20 Brigatinib was approved for Frontline NSCLC by the FDA. pretty impressive.

So, does anyone find it rather intriguing that the newest BOD selection, Horizon CEO Walbert also skippers a rare disease/rheumatic company? Lupus fits that portfolio perfectly. Also Horizon's newest FDA drug is a Thyroid Eye Medication that is absolutely killing it sales wise out of the gates. tripled the expectations for first quarter of its market life. One of the common medications needed to treat Thyroid Eye Disease happens to be Chronic Dry Eye treatments as patients typically have Bulging eye and blinking complications.

Now that Walbert can access AUPH file cabinets at what point does he click and say. Holy Crap this company with unencumbered assets and patent protections in Horizon's neck of the woods with a team that can already achieve sales ramps in rheumatic disease... Just gets me thinking about that
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AUPH News